Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347946 | 0.82 | DUT (0.46) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL20361557 | 0.81 | PDE2A (0.39) | DUTPDE2AGRM2 | |
| SCHEMBL15864648 | 0.80 | DUT (0.39) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL1409593 | 0.80 | DUT (0.45) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL21325251 | 0.80 | DUT (0.45) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL22414494 | 0.79 | DUT (0.45) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL2304488 | 0.78 | SCN8A (0.43) | DUTPDE2ARIPK1GRM2HTR2A | |
| SCHEMBL20206933 | 0.77 | DUT (0.50) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL20202148 | 0.77 | GRM2 (0.43) | DUTRIPK1GRM2HTR2AHTR2C | |
| SCHEMBL20347951 | 0.77 | DUT (0.42) | DUTRIPK1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188039-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2025-06-12 | — | — | US | disclosed |
| EP-3319939-B1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS NI LTD (GB) | 2024-11-27 | — | — | EP | disclosed |
| US-12098133-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11479531-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-10-25 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479531-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2648/4885RIPK1 4031/4885 |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2463/4885RIPK1 3869/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | DUT 2/4885PDE2A 2921/4885RIPK1 3321/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2463/4885RIPK1 3869/4885 |
| US-20250188039-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2463/4885RIPK1 3869/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | DUT 1/4885PDE2A 2775/4885RIPK1 3257/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | DUT 3/4885PDE2A 3293/4885RIPK1 3431/4885 |
| US-12098133-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2463/4885RIPK1 3869/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | DUT 2/4885PDE2A 2921/4885RIPK1 3321/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885PDE2A 2463/4885RIPK1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.